CorMedix (CRMD) Cost of Revenue (2016 - 2025)
CorMedix has reported Cost of Revenue over the past 13 years, most recently at $27.1 million for Q4 2025.
- Quarterly results put Cost of Revenue at $27.1 million for Q4 2025, up 1.14% from a year ago — trailing twelve months through Dec 2025 was $49.2 million (up 17.7% YoY), and the annual figure for FY2025 was $38.1 million, up 32.42%.
- Cost of Revenue reached $27.1 million in Q4 2025 per CRMD's latest filing, up from $11.2 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $27.1 million in Q4 2025 and bottomed at $332.0 in Q2 2022.
- Median Cost of Revenue over the past 5 years was $3.3 million (2023), compared with a mean of $5.6 million.
- The largest annual shift saw Cost of Revenue plummeted 99.15% in 2022 before it surged 2009668.97% in 2023.
- Over 5 years, Cost of Revenue stood at $48007.0 in 2021, then tumbled by 99.15% to $406.0 in 2022, then soared by 2009668.97% to $8.2 million in 2023, then soared by 228.76% to $26.8 million in 2024, then increased by 1.14% to $27.1 million in 2025.
- Business Quant data shows Cost of Revenue for CRMD at $27.1 million in Q4 2025, $11.2 million in Q3 2025, and $6.4 million in Q2 2025.